Covid 19 Research Clinical Trials by Shray Alag

D005764: Gastroesophageal Reflux

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (7)

	Name (Synonyms)	Correlation
drug2613	None - NA Wiki	0.71
drug2395	Mindfulness training Wiki	0.71
drug3798	Subacute rehabilitation Wiki	0.71

	Name (Synonyms)	Correlation
drug2880	Personalized ambulatory training Wiki	0.71
drug1875	IW-3718 Wiki	0.71
drug1331	Early rehabilitation Wiki	0.71
drug4650	placebo Wiki	0.18

Correlated MeSH Terms (3)

	Name (Synonyms)	Correlation
D004942	Esophagitis, Peptic NIH	0.71
D004932	Esophageal and Gastric Varices NIH	0.71
D003108	Colonic Diseases NIH	0.71

Correlated HPO Terms (2)

	Name (Synonyms)	Correlation
HP:0002020	Gastroesophageal reflux HPO	1.00
HP:0002040	Esophageal varix HPO	0.71

Clinical Trials

Navigate: Correlations HPO

There are 2 clinical trials

1 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors

The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard-dose proton pump inhibitors (PPIs).

NCT03561090

Conditions

Gastroesophageal Reflux Disease (GERD)

Interventions

Drug: IW-3718
Drug: placebo

MeSH:Gastroesophageal Reflux Esophagitis, Peptic

HPO:Gastroesophageal reflux

Primary Outcomes

Measure: Proportion of Overall Heartburn Responders

Time: Week 8

Secondary Outcomes

Measure: Proportion of Overall Heartburn Responders Among Participants With a Baseline Weekly Heartburn Severity Score (WHSS) ≥ 3

Time: Week 8

Measure: Percent Change From Baseline to Week 8 in WHSS

Time: Baseline, Week 8

Measure: Percent Change From Baseline to Week 8 in Weekly Regurgitation Frequency Score (WRFS)

Time: Baseline, Week 8

Measure: Proportion of Heartburn-Free (Daily Heartburn Severity Score [DHSS]=0) Days During the 8-Week Treatment Period

Time: up to Week 8

Measure: Proportion of Overall Regurgitation Responders

Time: Week 8

Measure: Proportion of Days When Heartburn Did Not Occur (DHSS=0) or Was Very Mild (DHSS=1) During the 8-Week Treatment Period

Time: Week 8

Measure: Proportion of Days When Regurgitation Did Not Occur (Daily Regurgitation Frequency Scores [DRFS]=0) or Rarely Occurred (DRFS=1) During the 8-Week Treatment Period

Time: Week 8

Measure: Proportion of Regurgitation-Free (DRFS=0) Days During the 8-Week Treatment Period

Time: Week 8

Measure: Change From Baseline to Week 8 in Each Modified Reflux Symptom Questionnaire Electronic Diary (mRESQ) Item

Time: Baseline, Week 8

Measure: Proportion of Nights With Difficulty Falling Asleep Due to GERD During the 8-Week Treatment Period

Time: Week 8

Measure: Proportion of Days With Nighttime Awakening Due to GERD During the 8-Week Treatment Period

Time: Week 8

Measure: Number of Degree of Relief (of Heartburn/Regurgitation/Overall GERD Symptoms) Responders

Time: up to Week 8

Measure: Change From Baseline to Week 8 in Heartburn/Regurgitation/Overall GERD Symptoms Bothersomeness

Time: Baseline, Week 8

Measure: Proportion of Days With Rescue Medication Use During the 8-Week Treatment Period

Time: up to Week 8

2 Endoscopy-related Phone Consultation During the COVID-19 Outbreak: Impact on Attendance and Patient/Consultant Perspectives From a Tertiary Australian Hospital

The aim of this study is to evaluate patient and consultant experiences with phone consultations for endoscopy-related outpatient appointments during the COVID-19 outbreak.

NCT04344964

Conditions

Colon Polyp
Colon Disease
Reflux, Gastroesophageal
Varices, Esophageal

Interventions

Other: None - NA

MeSH:Colonic Diseases Gastroesophageal Reflux Esophageal and Gastric Varices

HPO:Esophageal varix Gastric varix Gastroesophageal reflux

Primary Outcomes

Description: percentage of patients that did not answer phone calls (at least 3 calls) or with documented FTA for the retrospective group.

Measure: Failed to attend patients

Time: 2 months

Secondary Outcomes

Description: Assessed through an online/hardcopy questionnaire based on previous studies on telehealth (adapted from Barsom et al. 2020 - MSF and PAT-VC questionnaires). These are mostly Likert-scale response mode statements.

Measure: Patient satisfaction with the phone consult

Time: 2 months

Description: Assessed through an online/hardcopy questionnaire based on previous studies on telehealth (adapted from Barsom et al. 2020). These are mostly Likert-scale response mode statements.

Measure: Consultant satisfaction with the phone consult

Time: 2 months

HPO Nodes

HP:0002020: Gastroesophageal reflux

Genes 453

ZIC2 HLA-DQA1 TERT KCNA2 SLC1A4 POGZ COL7A1 NONO NRXN1 NODAL COL5A1 SHANK3 PGM3 LIMK1 SCN8A ERCC8 ORC6 CTHRC1 FOXG1 EXT2 COL7A1 EEF1A2 RHBDF2 SIX3 SYT1 ACTL6B GP1BB FGFR3 TYMP DSP MLXIPL HLA-DRB1 KAT6A CHMP1A SEC24C SYNJ1 SYT1 CPLX1 CAMK2B PAK1 LRP5 RNF125 STAG1 WWOX NSD2 SNRPB FBXL4 SLC25A24 DISP1 GAS1 FOXH1 MECP2 ELN MAGEL2 OCRL PSPH JMJD1C UFD1 CREBBP CCR6 HNRNPH2 ASXL1 FCSK DLL1 SIX3 ORC1 SEC31A ASPA GTF2I NECAP1 NUP62 NSD1 GABRB2 FOXG1 FOXH1 GABRA2 MUC5B DDOST CDON ADAR TCF4 NALCN TRAK1 GAS1 SCN3A STAG2 COL13A1 SLC46A1 TMTC3 COL5A2 SPOP CYFIP2 PIK3CD NODAL NUP214 BRAF TRIP4 CACNA1B VAMP1 KMT2A SHH DISP1 RAD21 MECP2 TRMT10C GLI2 COL1A1 SEC23A HIVEP2 ITCH RERE BLM DISP1 TSPYL1 TWNK SLC13A5 FGF8 PSAP GABRA5 TDGF1 SLC2A10 ATAD1 SLC19A2 GLI2 FGF8 NIPBL TRAPPC12 TWIST1 MECP2 FGFR1 HLA-DRB1 CREBBP GNAS TBX4 SLC9A6 LETM1 NIPBL SRPX2 ATN1 CDKL5 RPL10 FMR1 CDON GRIN2D STAG2 NEDD4L DNM1 SIX3 RETREG1 RAI1 LBR ATP11A SAMD9 CAMTA1 RAI1 LAMA2 DDOST PHGDH ORC4 RERE ALMS1 ZIC2 HDAC8 ATRX KCNQ2 PUF60 LONP1 GABRG2 RPL10 TOP3A FGF8 ABCA3 DPP9 CSPP1 SFTPA1 SHH TSPYL1 ARV1 STXBP1 SON CNTNAP2 RET STAG2 ABCD4 PCGF2 KCNQ3 NODAL SLC1A2 RRM2B SKI NOS1 PTCH1 ZIC2 SMC1A CLTC CTCF GAS1 CNTNAP1 STAC3 PIGN TCF4 NTRK2 KCNB1 TIMM22 NEXMIF DYRK1A ASCC1 KNSTRN FLCN CDON TECPR2 MEIS2 POLG CDKN1A HCN1 IRF5 MSL3 CCN2 CAV1 PTCH1 GMNN MAP3K7 GLI2 SLC6A3 CCDC47 TCF4 SLC25A1 FARSB AARS1 PACS1 RPL10 CHD7 SLC25A4 CENPT DHCR7 SCN9A COL13A1 PIGN SMC1A FAM13A CHAT NPHS1 COG7 DYRK1A SH2B1 SLC18A3 CDKN1B SMC1A MEN1 ASCL1 MRPS34 KIF1A FBN1 ADNP NRXN1 CCR6 CDK19 SETD2 AMER1 RREB1 SLC35A2 ARVCF ATRX NEPRO MSR1 CLIP2 TBX1 PIGT SETD5 POGZ SYNGAP1 PPP3CA GEMIN4 ERMARD SFTPC KIAA0586 KLHL7 PRKCSH BAZ1B ZSWIM6 WHCR MAP3K7 IRF5 RRM2B AFF4 RFC2 SIX3 AP3B2 TDGF1 EBF3 KAT6B CACNA1A CDKN2C SLC6A3 USP7 ATRX FGF12 SEMA3E SHANK3 SFTPA2 SLC35A2 CDON FLNA ADGRG1 KMT2A RAD21 ALDH18A1 CCDC22 MAGEL2 TBC1D24 PARN MAP1B PARS2 PPM1D MED12L GLRA1 RAI1 CAV1 ZIC2 PI4KA AFF4 ARID2 HDAC8 CDC6 SMG9 ALDH18A1 NONO FOXH1 EXT2 MYMK GPHN UBA5 ARF1 FGF8 PHOX2B SHROOM4 ATRX GABRD POLG2 EP300 KCNAB2 TGIF1 CRLF1 WAC POLG2 PIGN TERT DHCR7 ADAMTS2 PTCH1 HRAS ARFGEF2 AGRN TDGF1 ERCC6 SNAP25 SHH WNK1 ELP1 LTBP4 ASXL1 GLI2 MID1 SKI CLCN4 CREBBP DHDDS GAS1 FOXG1 WASHC5 GALC NEXMIF RERE TFAP2A COMT TBX1 TGIF1 FLNA GTF2IRD1 SLC5A7 NUS1 KCNA2 NFIX DEAF1 SKI PTCH1 UBA5 DALRD3 ADAT3 YWHAG SMC3 FOXH1 STAG1 TAF1 FLII NALCN CNKSR2 TGIF1 SALL1 SMC3 RTEL1 STN1 APC2 PIEZO2 PIEZO1 SZT2 SEC63 SLC6A5 GLRB TDGF1 DLL1 PORCN CCN2 SHH TGIF1 EHMT1 CTBP1 ATP7A FGFR1 MYO9A FGFRL1 CHRNA3 HLA-DQB1 POLG MMP1 ELN WDR26 CHAMP1 SOX5 ATP6V1A ELP1 POLR2A NODAL SYT2 DDC MCEE ATP6 TBL2 DLL1 ARNT2 MED12 CDKN2B SMC1A HIRA TERC IQSEC2 KIAA0319L DLL1 SSR4 GNB5 PRDM16 PYCR1 DISP1

Protein Mutations 1

D961H

SNP 0

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials

HPO Nodes

HP:0002020: Gastroesophageal reflux

Genes 453

Protein Mutations 1

D961H

SNP 0

Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports MeSH Reports HPO Reports

Report Sections

See All Reports

D005764: Gastroesophageal Reflux

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (7)

Correlated MeSH Terms (3)

Correlated HPO Terms (2)

Clinical Trials

1 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors Click for details

NCT03561090

Conditions

Interventions

MeSH:Gastroesophageal Reflux Esophagitis, Peptic

HPO:Gastroesophageal reflux

Primary Outcomes

Secondary Outcomes

2 Endoscopy-related Phone Consultation During the COVID-19 Outbreak: Impact on Attendance and Patient/Consultant Perspectives From a Tertiary Australian Hospital Click for details

NCT04344964

Conditions

Interventions

MeSH:Colonic Diseases Gastroesophageal Reflux Esophageal and Gastric Varices

HPO:Esophageal varix Gastric varix Gastroesophageal reflux

Primary Outcomes

Secondary Outcomes

HPO Nodes

Genes 453

Protein Mutations 1

SNP 0

HPO

HPO Nodes

Genes 453

Protein Mutations 1

SNP 0

Reports

1 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors

2 Endoscopy-related Phone Consultation During the COVID-19 Outbreak: Impact on Attendance and Patient/Consultant Perspectives From a Tertiary Australian Hospital